



Regulations of the Diabetes and Cardiovascular Disease (D&CVD) Study Group

Revised and approved by the General Assembly during the 15th Annual Meeting,
Tel Aviv, May 2023

1. The Study Group is called the **Diabetes and Cardiovascular Disease Study Group**, hereinafter referred to as the **D&CVD Study Group**.
2. The **D&CVD Study Group** acts as a reference group for **European Association for the Study of Diabetes (EASD)** in matters related to promote advancement of knowledge on all aspects of Cardiovascular Disease and Diabetes through active co-operation between interested Diabetologists and other specialists, particularly Cardiologists. It works actively for the establishment of European collaborative studies and acts in matters related cardiovascular disease and diabetes. Furthermore, the **D&CVD Study Group** aims to bring together researchers working in the field of cardiovascular disease in diabetes mellitus, exchange experiences in research and promote discussions during regular meetings, and may work actively for establishment of European and International collaborative studies and act as a reference group in matters related to cardiovascular disease and diabetes.

The Group shall meet on an annual basis for a scientific meeting and a business meeting. The time and place of the meetings will be decided by the Executive Committee. In addition to the annual meeting the **D&CVD Study Group** may promote seminars, workshops and any other scientific activity aiming to improve the awareness about diabetes and CVD. If such activity is to be held in the name of **D&CVD Study Group** it needs approval by the **D&CVD Study Group** Committee. The financial support for the annual meeting will be sought from pharmaceutical companies; if financial problems arise the organisers will be allowed to take registration fee from all participants. The



financial support should be used for accommodation and meals during the annual meeting etc. The travel expenses should be covered by the members. However, the Members of the Executive Committee may give travel grants to selected members of the group who present an abstract during the meeting and who need financial support.

4. Membership of the **D&CVD Study Group** shall be open to all members of the EASD and such other persons as the committee of the **D&CVD Study Group** consider eligible.

5. The membership of the **D&CVD Study Group** is free.

6. Administration of the **D&CVD Study Group** shall be in the hands of the **D&CVD Study Group** Committee; this Committee should consist of a President, a Vice President, a Treasurer, and 5 members. A Secretary could be also nominated. The members of the Committee are re-eligible. The Secretary will expire every year. Each member of the Committee has one vote, when necessary, the President will have a casting vote.

The Executive Committee is formed by:

Prof Antonio Ceriello, President (expires 2025)

Prof Eberhard Standl, Vice President (expires 2024)

Prof Oliver Schnell, Treasurer (expires 2024)

Prof Doina Catrinoiu (expires 2025)

Prof Paul Valensi (expires 2024)

Prof Jan Skrha (expires 2025)

Prof Nebjosa Lalic (expires 2025)

Dr Dario Rahelic (expires 2025)

Dr Baruch Itzhak, Secretary (expires 2025)



7. The finances of the Study Group shall be managed at the discretion of the Committee in pursuit of the aims of the Study Group (para. 3 above). Proper books of account shall be kept by the **D&CVD Study Group** Treasurer.

8. In the event of the Group being dissolved, all surpluses, debts and liabilities shall be discharged to a charitable diabetes account.

Prof. Antonio Ceriello
President D&CVD Study Group